The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria

• Published in: Journal of antimicrobial chemotherapy Vol. 38; no. 2; pp. 271 - 281
• Main Authors: Bowker, K. E., Wootton, M., Holt, H. A., Reeves, D. S., MacGowan, A. P.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.08.1996
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Infective Agents - pharmacology; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Bacteria, Anaerobic - drug effects; Biological and medical sciences; Fluoroquinolones; Gram-Negative Bacteria - drug effects; Gram-Positive Bacteria - drug effects; Medical sciences; Microbial Sensitivity Tests; Naphthyridines - pharmacology; Pharmacology. Drug treatments; Antibiotic; Fluoroquinolone derivative; Sensitivity resistance; Anaerobe; Bacteria; Antibacterial agent; In vitro; Clinical isolate; Comparative study
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/38.2.271

The in-vitro activity of trovafloxacin and nine other antimicrobials was determined for 413 non copy anaerobic clinical isolates. Trovafloxacin was the most active quinolone tested with an MIC90 of 0.5 mg/L against Gram-positive cocci (n = 75); MIC90 of 4 mg/L against Gram-positive bacilli (n = 151); MIC90 of 0.5 mg/L for Gram-negative cocci (n = 12) and MIC90 of 1 mg/L for Gram-negative bacilli (n = 175). Overall the MIC90 of trovafloxacin was 1 mg/L which was equivalent to co-amoxiclav and one dilution higher than that of imipencm. The other seven comparators, including clindamycin and metronidazole, had higher MIC90 values than trovafloxacin. Trovafloxacin is likely to have clinically useful activity against anaerobes from human infection.